

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

(1) RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND (2) NON-COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

The board (“**Board**”) of directors (“**Directors**”) of Link-Asia International MedTech Group Limited (the “**Company**”) announces the following changes:

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

Mr. Chak Chi Shing (“**Mr. Chak**”) has resigned as an independent non-executive Director and the chairman of the audit committee of the Company with effect from 23 September 2023 due to his own business commitment.

Mr. Chak has confirmed that he has no disagreement with the Board and there is no matter regarding his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board would like to express its sincere gratitude to Mr. Chak for his valuable contribution to the Company during her tenure of office as an independent non-executive Director.

Following Mr. Chak’s resignation, Mr. Wu Chi King (“**Mr. Wu**”) has been appointed as the chairman of the audit committee of the Company and will cease to be the chairman of the remuneration committee but remain as a member of the remuneration committee with effect from 23 September 2023.

Mr. Li Huiwu (“**Mr Li**”) will be appointed as the chairman of the remuneration committee.

NON-COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

Following the resignation of Mr. Chak, the Board comprises six members, including four executive Directors and two independent non-executive Director. The current number of independent non-executive Director is less than three as required under Rule 3.10(1) of the Listing Rules.

Mr. Chak was also the chairman of the audit committee of the Company. Following Mr. Chak's resignation, the Board is unable to fulfil the requirement of having three members on the audit committee under Rule 3.21 of the Listing Rules.

The Company considers that the failure of meeting the requirements of Rules 3.10(1) and 3.21 of the Listing Rules are temporary in nature and the Company will use its best endeavors to identify a suitable candidate to be additional independent non-executive Director within three months from the date of Mr. Chak's ceasing to be an independent non-executive Director pursuant to Rules 3.11 and 3.23 of the Listing Rules to meet the requirements under the Listing Rules.

The Company will ensure its compliance with the number and the composition of the independent non-executive Directors and the Board committees under the Listing Rules. The Company will make further announcement(s) as and when appropriate.

By order of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and executive Director

Hong Kong, 22 September 2023

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Liu Zhiwei, Ms. Lin Xiaoshan and Ms. Bian Sulan as executive Directors; Mr. Li Huiwu, Mr. Wu Chi King and Mr. Chak Chi Shing as independent non-executive Directors.